UCL Technology Fund invests in Covid-19 research
UCL Technology Fund is pleased to announce that it has funded UCL Cancer Institute research project to repurpose a sophisticated antibody engineering approach to develop a new treatment against Covid-19.
A new project, led by Dr Martin Pule, Senior Lecturer in Haematology and Professor Kerry Chester, Department of Oncology, will investigate pivoting existing research used in the fight against cancer by creating a unique ‘cocktail’ of recombinant antibodies capable of preventing the virus from entering cells and removing it from circulation.
Scientists will identify and clone the antibodies from genetic material produced by white blood cells from recovered Covid-19 patients who have made effective antibodies to the virus. The work involves extracting, amplifying and then analysing the antibody genes from many millions of cells - and using this information to create vast antibody libraries.
Dr Anne Lane, CEO, UCLB said:
By enabling this collaboration we are engaging world-leading cancer research in the fight against Covid-19. Our mission is to commercialise the exceptional ideas of UCL researchers, to benefit society and the economy – and this initiative from UCL’s Cancer Institute is a fabulous example.
Simon Goldman, Investment Director of UCL Technology Fund said:
We’re honoured to be able to support the world-leading team at UCL Cancer Institite in redeploying their antibody-engineering expertise to help tackle COVID-19.